Literature DB >> 19247216

Mucolipidosis type IV: the effect of increased lysosomal pH on the abnormal lysosomal storage.

Aviram Kogot-Levin1, Marsha Zeigler, Asher Ornoy, Gideon Bach.   

Abstract

Mucolipidosis type IV (MLIV) is a neurodegenerative channelopathy that is caused by the deficiency of TRPML1 activity, a nonselective cation channel. TRPML1 is a lysosomal membrane protein, and thus, MLIV is a lysosomal storage disorder. The basic, specific function of TRPML1 has not been yet clarified. A recent report (Soyombo AA, Tjon-Kon-Sang S, Rbaibi Y, Bashllari E, Bisceglia J, Muallem S, Kiselyov K: J Biol Chem 281:7294-7301, 2006) indicated that TRPML1 functions as an outwardly proton channel whose function is the prevention of overacidification of these organelles. Thus, in MLIV the lysosomal pH is lower than normal. Furthermore, attempts by these investigators to increase slightly the lysososmal pH with either Nigericin or Chloroquine suggested corrective effect of the abnormal storage in MLIV cells. We investigated this approach using these agents with cultured fibroblasts from severely affected and milder patients. Our data indicated that there was no reduction in the total number of storage vesicles by either agent, although Nigericin resulted in a change in the nature of the storage materials, reducing the presence of lamellated substances (lipids) so that the storage vesicles contained predominantly granulated substances. On the other hand, transfection with the normal MCOLN1 cDNA (the gene coding for TRPML1) resulted in the removal of almost all the storage materials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247216     DOI: 10.1203/PDR.0b013e3181a1681a

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

Review 1.  Fig4 deficiency: a newly emerged lysosomal storage disorder?

Authors:  Colin Martyn; Jun Li
Journal:  Prog Neurobiol       Date:  2012-11-16       Impact factor: 11.685

2.  Design and investigation of a series of rhodamine-based fluorescent probes for optical measurements of pH.

Authors:  Quinn A Best; Ruisong Xu; Matthew E McCarroll; Lichang Wang; Daniel J Dyer
Journal:  Org Lett       Date:  2010-07-16       Impact factor: 6.005

Review 3.  Mucolipidosis type IV: an update.

Authors:  Kazuyo Wakabayashi; Ann Marie Gustafson; Ellen Sidransky; Ehud Goldin
Journal:  Mol Genet Metab       Date:  2011-06-16       Impact factor: 4.797

4.  Zinc dyshomeostasis is linked with the loss of mucolipidosis IV-associated TRPML1 ion channel.

Authors:  Jonathan L Eichelsdoerfer; Jeffrey A Evans; Susan A Slaugenhaupt; Math P Cuajungco
Journal:  J Biol Chem       Date:  2010-09-23       Impact factor: 5.157

5.  Cellular zinc levels are modulated by TRPML1-TMEM163 interaction.

Authors:  Math P Cuajungco; Luigi C Basilio; Joshua Silva; Thomas Hart; Jonathan Tringali; Cheng-Chang Chen; Martin Biel; Christian Grimm
Journal:  Traffic       Date:  2014-09-02       Impact factor: 6.215

6.  Lysosomal storage causes cellular dysfunction in mucolipidosis II skin fibroblasts.

Authors:  Takanobu Otomo; Katsumi Higaki; Eiji Nanba; Keiichi Ozono; Norio Sakai
Journal:  J Biol Chem       Date:  2011-08-16       Impact factor: 5.157

Review 7.  The role of TRPMLs in endolysosomal trafficking and function.

Authors:  Kartik Venkatachalam; Ching-On Wong; Michael X Zhu
Journal:  Cell Calcium       Date:  2014-10-28       Impact factor: 6.817

8.  Lysosomal TRPML1 Channel: Implications in Cardiovascular and Kidney Diseases.

Authors:  Guangbi Li; Pin-Lan Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Aberrant Ca2+ handling in lysosomal storage disorders.

Authors:  Kirill Kiselyov; Soichiro Yamaguchi; Christopher W Lyons; Shmuel Muallem
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

10.  Proteomics analysis of a human brain sample from a mucolipidosis type IV patient reveals pathophysiological pathways.

Authors:  Ayelet Vardi; Amir Pri-Or; Noa Wigoda; Yulia Grishchuk; Anthony H Futerman
Journal:  Orphanet J Rare Dis       Date:  2021-01-21       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.